Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26723526)

Published in J Control Release on December 23, 2015

Authors

Ryan S Teller1, David C Malaspina2, Rachna Rastogi3, Justin T Clark4, Igal Szleifer5, Patrick F Kiser6

Author Affiliations

1: Department of Bioengineering, University of Utah, 20 S 2030 E, Salt Lake City, UT 84112, United States; Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States.
2: Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States; Chemistry of Life Processes Institute, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States.
3: Department of Bioengineering, University of Utah, 20 S 2030 E, Salt Lake City, UT 84112, United States.
4: Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States.
5: Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States; Chemistry of Life Processes Institute, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States; Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States.
6: Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States; Chemistry of Life Processes Institute, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, United States; Department of Obstetrics and Gynecology, Northwestern University, 250 E. Superior, Suite 03-2303, Chicago, IL 60611, United States. Electronic address: patrick.kiser@northwestern.edu.

Articles cited by this

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91

Elementary osmotic pump. J Pharm Sci (1975) 2.69

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03

Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58

A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy. J Control Release (2015) 1.55

Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49

Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38

State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev (2012) 1.37

Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34

HPMC-matrices for controlled drug delivery: a new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharm Res (1999) 1.32

Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol (2013) 1.31

High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav (2012) 1.30

An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17

A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16

Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10

Contraceptive vaginal rings: a review. Contraception (2010) 1.04

Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04

Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One (2014) 1.00

An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt) (2008) 1.00

Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release (2003) 0.99

Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model. Antimicrob Agents Chemother (2013) 0.97

Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm (2010) 0.96

Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother (2014) 0.93

Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights. J Control Release (2005) 0.91

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84

A new model describing the swelling and drug release kinetics from hydroxypropyl methylcellulose tablets. J Pharm Sci (1999) 0.83

Intravaginal flux controlled pump for sustained release of macromolecules. Pharm Res (2014) 0.81

Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res (2013) 0.79

A mechanistic modelling approach to polymer dissolution using magnetic resonance microimaging. J Control Release (2010) 0.78

Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach. BJOG (2014) 0.78

Controlled drug release from polymeric devices. I. Technique for rapid in vitro release studies. J Pharm Sci (1974) 0.76